World Rugby star Dan Carter tested positive

Dan Carter in action for Racing Metro earlier this year.
Please help us by reporting dead videos.

World Rugby’s player of the year Dan Carter has been tested positive for a banned substance but his agent says that he had a Therapeutic Use Exemptions (TUEs).

A reports surfaced on Thursday in French newspaper L’Equipe which said that Carter and his former All Black team mate Joe Rokocoko both had “anomalies” in their urine test conducted around the time of the French Top 14 final on 24 June.

However Simon Porter who works for the players’ management company Essentially has said that the pair had been given Therapeutic Use Exemptions (TUEs) for the medicine while they recovered from injuries.

“Our understanding and assurances we’ve had are all the documents around TUEs were in place,” Porter told the New Zealand Herald newspaper.

The use of corticosteroids is fairly common in modern day sports and it helps players recover from minor injuries faster. Typically corticoids are used to treat inflammation or joint pain .

Porter said that the players had been aware of the test findings for some time and they were both relaxed about it as their club doctor had done the necessary paperwork.

Player contracts manager Porter added that the tests were done the day before the Top 14 final and explained that Carter was suffering with a calf injury while Rokocoko had a knee problem.

Racing Metro went on to beat Toulon 29-21 in the Top14 final which was staged at Barcelona’s Nou Camp soccer stadium due to the Euro 2016 tournament being held in France.

Leave a Reply

Your email address will not be published. Required fields are marked *


This site uses Akismet to reduce spam. Learn how your comment data is processed.

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.